33 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
3 Jun 24
Report of Foreign Private Issuer
8:05am
for the development of an innovative tendon repair technique.
The investigator-initiated Phase I/II trial plans to recruit up to 46 patients
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
AND THEIR CRITICAL ROLE IN INFLAMMATION Recruit other immune cells Defend against pathogens Cleanup senescent or dead cells Control tissue homeostasis
6-K
EX-99.1
5eq9cfk
13 Dec 21
Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece
8:00am
6-K
EX-99.1
nqzi6vw3yz uo576jc6
22 Nov 21
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
8:00am
6-K
EX-99.1
vwc9gtdkkpvu34std4ch
10 Nov 21
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
8:00am
6-K
EX-99.1
sxtwg88l9trhc6vro7x
22 Sep 21
Report of Foreign Private Issuer
6:02am
6-K
EX-99.1
1d0tip7
16 Aug 21
Report of Foreign Private Issuer
6:12am
6-K
EX-99.1
zkh4xmd
9 Aug 21
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update
8:00am
424B5
bdk47qcfp7xu na
10 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
flmrr485s
9 Feb 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-99.1
2478v5ut 2c
3 Feb 21
Current Report
7:55am
6-K
EX-99.1
63ecws68n1cndyc1
3 Dec 20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:00am
6-K
EX-99.1
gsi ml2gpvh46ps
3 Nov 20
Current report (foreign)
9:14am
6-K
EX-99.1
iugsy fblq
27 Oct 20
Report of Foreign Private Issuer
8:03am
6-K
EX-99.1
3528c30xva1uxccip
22 Oct 20
Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:49am
424B5
mo5 1ndlxjqzsxc
22 Oct 20
Prospectus supplement for primary offering
8:45am